Immatics (IMTX) Projected to Post Earnings on Tuesday

Immatics (NASDAQ:IMTX) is expected to be releasing its Q3 2026 results before the market opens on Tuesday, November 17th. Analysts expect the company to announce earnings of ($0.49) per share and revenue of $12.18 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 20, 2026 at 12:30 PM ET.

Immatics (NASDAQ:IMTX) last announced its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). The business had revenue of $10.44 million during the quarter, compared to the consensus estimate of $12.42 million. Immatics had a negative net margin of 495.71% and a negative return on equity of 47.41%. On average, analysts expect Immatics to post ($1.99) EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

Immatics Stock Up 1.1%

IMTX stock opened at $6.43 on Tuesday. Immatics has a twelve month low of $6.09 and a twelve month high of $12.41. The business’s fifty day moving average is $7.95 and its 200-day moving average is $9.48. The company has a market cap of $878.92 million, a P/E ratio of -3.46 and a beta of 1.38.

Insider Transactions at Immatics

In other Immatics news, Director Perceptive Advisors Llc bought 863,060 shares of the firm’s stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $8.69 per share, for a total transaction of $7,499,991.40. Following the transaction, the director directly owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This trade represents a 8.31% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Analysts Set New Price Targets

IMTX has been the topic of a number of analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immatics in a research report on Friday, September 18th. Wall Street Zen lowered Immatics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Stifel Nicolaus assumed coverage on shares of Immatics in a report on Tuesday, October 13th. They set a “buy” rating and a $15.00 target price for the company. Mizuho set a $21.00 price target on Immatics in a research report on Thursday, October 29th. Finally, Jefferies Financial Group set a $17.00 price objective on Immatics in a report on Tuesday, August 25th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immatics presently has a consensus rating of “Moderate Buy” and an average price target of $19.00.

About Immatics

Immatics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Founded in Germany in 2000, the company uses its target-discovery and development platforms to identify cancer-associated targets and create therapies designed to direct the immune system against tumor cells.

Its pipeline includes engineered T-cell receptor (TCR) T-cell therapies, which modify a patient’s T cells to recognize specific tumor targets, as well as TCR bispecific therapies designed to connect T cells with cancer cells.